Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q1 2020 · 10-Q
Revenue—
Net Income-$18.73M-$18.73MN/M vs Q1 2019 EPS Diluted-$0.57-$0.57N/M vs Q1 2019 Operating Income-$19,022,000N/M Operating Cash Flow-$21,694,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
Free Cash Flowderived-$23,083,000N/M ended Mar 31, 2020 · filed May 7, 2020 · 37 d after period end